Related Experiment Video
Updated: Jun 17, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Psoriatic arthritis: a review.
Anne Amherd-Hoekstra1, Helmut Näher, Hanns-Martin Lorenz
1University Hospital Heidelberg, Department of Dermatology, Heidelberg, Germany. anne.hoekstra@med.uni-heidelberg.de
Summary
Psoriatic arthritis (PsA) is a chronic inflammatory condition impacting quality of life. Early diagnosis and treatment, including Disease-Modifying Antirheumatic Drugs (DMARDs) and TNF-alpha antagonists, are crucial for managing PsA effectively.
Area of Science:
- Rheumatology and Immunology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is an immunologically triggered, chronic inflammatory arthropathy.
- PsA significantly impacts patients' quality of life, necessitating early diagnosis and intervention.
- Multidisciplinary care involving dermatologists and rheumatologists is key for effective management.
Purpose of the Study:
- To outline the diagnostic and therapeutic strategies for Psoriatic Arthritis.
- To highlight the role of early intervention in managing PsA.
- To discuss the evolving role of targeted therapies in PsA treatment.
Main Methods:
- Review of current literature and clinical guidelines for PsA diagnosis and management.
- Discussion of pharmacological treatment options, from NSAIDs to advanced biologics.
- Emphasis on the importance of integrated dermatological and rheumatological care.
Main Results:
- Mild PsA can be managed with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
- Moderate to severe PsA with oligo- to polyarticular involvement requires Disease-Modifying Antirheumatic Drugs (DMARDs).
- Tumor necrosis factor (TNF) plays a critical role in PsA inflammation, making TNF-alpha antagonists important second-line therapies.
Conclusions:
- Early diagnosis and prompt, adequate therapy are essential for managing Psoriatic Arthritis.
- Treatment approaches range from symptomatic relief to disease-modifying agents and biologics.
- Targeting TNF-alpha is a significant advancement in PsA treatment, particularly for refractory cases.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...